Pradefovir mesylate
CAS: 625095-61-6
Ref. 3D-AAB09561
5mg | 745,00 € | ||
10mg | 1.121,00 € | ||
25mg | 1.828,00 € | ||
50mg | 2.925,00 € |
Produktinformation
- 9-(2-{[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphinan-2-yl]methoxy}ethyl)-9H-purin-6-amine methanesulfonate (1:1)
- 9H-Purin-6-amine, 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-, methanesulfonate (1:1)
- 9H-Purin-6-amine, 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-, monomethanesulfonate
- Hepavir B
- MB-06866,MB-6866,Hepavir B,Remofovir mesylate
- Mb 06866Q
- Pradefovir Mesilate
- Remofovir mesylate
Pradefovir mesylate is a prodrug that is converted to pradefovir in the human body. It has been shown to be an effective antiviral drug for the treatment of HIV infection and hepatitis B virus. Pradefovir prevents replication of the virus by blocking reverse transcriptase, which is required for viral DNA synthesis. In vitro studies have found that it also inhibits other members of the hepadnavirus family, such as hepatitis C and D, through its action on reverse transcriptase. This drug has a low toxicity profile in animal studies and can be given orally or intravenously. The drug's matrix effect may cause it to accumulate in regions of high fat content, such as the liver and spleen, although this property may also help it penetrate areas where viruses replicate, such as CD4+ cells.
Chemische Eigenschaften
Technische Anfrage zu: 3D-AAB09561 Pradefovir mesylate
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.